Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma

Inclusion Criteria: * Subject must be histologically or clinically proven HCC, inoperable, no indication of local treatment and has measurable lesions. * Subject must to be the first experience of TACE. * Subject has no extra-hepatic tumor and no obstruction of main portal vein. * Subjects must have fully recovered from previous treatment (at least 4 weeks interval is needed from prior chmotherapy or radiation therapy). * ECOG performance status 0-2 * Child-pugh Class A or B * Subject must have adequate functions of bonemarrow, renal, circulatory organs and appropriate examination results as below: 1. Serum Total Bilirubin 2.0mg/mL 2. WBC 3000/mm3 3. PLT 50000/mm3 4. Hb 9.0g/dL 5. Creatinine ; upper normal limit (UNL) 6. BUN 25mg/dL * Written informed consent Exclusion Criteria: * Subject has extra hepatic metastasis. * Tumor thrombosis exists at main portal vein. * Remarkable artery-portal vein shunt or veno-arterial shunt. * Uncontrollable ascites or pleural effusion. * History of severe hypersensitivity. * Any previous TACE or TAE for HCC. * Any previous chemotherapy using epirubicin or CDDP. * Complications as below (except chronic hepatitis or liver cirrhosis) 1. Severe heart disease 2. Myocardial infarction within 6 months 3. Renal insufficiency 4. Active infections (except virous hepatitis) 5. Gastrointestinal bleeding 6. Active double cancer 7. Hepatic encephalopathy or heavy mental disorder. * Pregnancy or lactation women, or women with suspected pregnancy or men with willing to get pregnant. * Any subject judged by the investigator to be unfit for any reason to participate in the study.